MPK16 Antibody

Introduction to MUC16 and Antibody Targeting

MUC16 (Mucin-16) is a transmembrane glycoprotein overexpressed in epithelial cancers, including ovarian, pancreatic, and lung cancers . Its extracellular domain, CA125, is a well-established biomarker for ovarian cancer monitoring . Antibodies targeting MUC16 are designed to exploit its overexpression on cancer cells for diagnostic and therapeutic purposes .

Cancer Therapy

MUC16 antibodies are engineered for multiple modalities:

Observed Effects:

• Tumor Regression: huAR9.6 reduced pancreatic tumor growth by 60% in orthotopic models .

• Immune Evasion Blockade: ch5E6 inhibits MUC16-mediated NK cell suppression .

Diagnostic Imaging

• Radioimmunoconjugates: Antibodies like huAR9.6 labeled with 89Zr enable PET imaging of MUC16-positive tumors, showing tumor-to-background ratios >5:1 .

Phase I Study of DMUC5754A (ADC)

• Population: Advanced ovarian (n=66) and pancreatic (n=11) cancers .

• Safety: Grade ≥3 adverse events included neutropenia (9–17%) and fatigue (7%).

• Efficacy: Confirmed responses in 7 ovarian cancer patients; stable disease in 6 patients >6 months .

Challenges

• Antigen Shedding: Circulating CA125 may reduce ADC efficacy by binding antibodies before tumor targeting .

• Off-Target Toxicity: Hepatic uptake observed in imaging studies due to Fc receptor interactions .

Future Directions

• Bispecific Antibodies: Combining MUC16 targeting with immune checkpoint inhibitors (e.g., PD-1) .

• Glycoengineered Antibodies: Modifying glycosylation patterns to enhance binding and reduce immunogenicity .